Therapeutic effects of cetirizine in delayed pressure urticaria: Clinicopathologic findings

Kontou-Fili, Kalliopi; Maniatakou, G; Demaka, Panayiota; Gonianakis, Michael I.; Palaiologos, G.; Aroni, Kyriaki

doi:10.1016/0190-9622(91)70163-v

Cited by 60 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Istnieją liczne badania wykazujące korzyści ze stosowania większych dawek leków przeciwhista minowych w terapii niektórych pacjentów [100][101][102]. Potwierdzają one wcześniejsze obserwacje w stosun ku do leków przeciwhistaminowych I generacji [103,104].…”

Section: Czy W Leczeniu Pokrzywki Należy Preferować Nowoczesne Preparunclassified

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Zuberbier¹,

Aberer²,

Asero³

et al. 2015

View full text Add to dashboard Cite

Section: Czy W Leczeniu Pokrzywki Należy Preferować Nowoczesne Preparunclassified

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Zuberbier¹,

Aberer²,

Asero³

et al. 2015

View full text Add to dashboard Cite

“…Antihistamines are usually very helpful in dermographism and moderately effective in solar and heat urticaria but often fail in delayed pressure urticaria [103]. A beneficial effect of higher doses of cetirizine has been shown in cholinergic urticaria (20 mg/day) and in delayed pressure urticaria (30 mg/day) [103].…”

Section: Tailoring Treatment To Other Clinical Patterns Of Urticaria mentioning

confidence: 98%

Urticaria: current and future treatments

Borzova

Grattan

2007

Expert Review of Dermatology

View full text Add to dashboard Cite

Urticaria is a common disorder with diverse clinical presentations. Correct recognition of the different clinical patterns promotes more effective treatment. Management involves treatment of any identifiable external causes, including infection, avoidance of drug, food and physical triggers and the appropriate use of pharmacological therapies. These can be divided into first-, second-and third-line approaches. The choice of treatment will be influenced by many factors, including drug licensing, safety, pattern of disease, disease severity, pharmacoeconomic considerations and patient preference. H1 antihistamines are the mainstay of treatment of most patterns of urticaria and are effective in the majority of patients with mast cell-mediated disease. Second-generation antihistamines have a better therapeutic index and improved pharmacodynamic properties compared with older 'classic' antihistamines and should be prescribed preferentially for chronic urticaria. Patients who are unresponsive to H1 antihistamines at full dose may require short-term treatment with oral corticosteroids but their long-term use for urticaria should be avoided whenever possible on account of the risk of serious adverse effects. Antileukotrienes and alternative second-line agents, prescribed off licence, can be helpful for patients who respond poorly to antihistamines when taken in conjunction but a better evidence base is needed to guide prescribing. Third-line immunosuppressive therapies can be considered for debilitating urticaria, especially for patients with corticosteroid-dependent chronic disease, and may have some potential to modify the natural course of the illness. Possible new therapeutic approaches on the horizon include new H1 antihistamines, H4 receptor antagonists, a histidine decarboxylase inhibitor under development and biological agents that target histamine-releasing autoantibody production and function.

show abstract

“…New-generation antihistamines also exert anti-inflammatory effects such as cytokine release from basophils and mast cells [69,70]. The effect of antihistamines in urticaria is dose dependent [64,113] and higher dosages are usually well tolerated, but care must be taken as side-effects such as sedation can occur more frequently in some cases at higher dosages. Fexofenadine, loratadine, and mizolastine are taken once daily.…”

Section: First Line Of Treatmentmentioning

confidence: 99%

Current advances in the management of urticaria

Khalaf

Tan

2008

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Urticaria is a relatively common autoimmune/autoreactive skin disorder that may severely impair quality of life. Although rarely life-threatening, widespread urticaria and its associated angioedema can be an extremely disabling and difficult-to-treat condition. Patients may suffer symptoms such as pruritus and disfigurement due to wheals for years or decades. Urticaria is caused by cutaneous mast-cell degranulation attributed to immunological, non-immunological, and idiopathic causes. The last decade has seen some notable advances in the understanding of the etiology and pathogenesis of common forms of urticaria and their management. Furthermore, the wide diversity in urticaria subtypes has been identified and this reflects a partial understanding of the causes or factors that trigger it as well as the molecular and cellular mechanisms that are involved in its physiopathology. In addition, new instruments for diagnosing urticaria variants and for assessing quality of life in urticaria patients have been developed. Finally, several clinical trials have demonstrated the efficacy of novel treatment approaches for urticaria, while other therapeutic concepts are under development. The objective of this article was to review the literature to be able to offer the readers comprehensive and updated information on the basic etiological and physiopathological mechanisms and to make special emphasis on the current management of urticaria, thus promoting continuous medical education.

show abstract

Therapeutic effects of cetirizine in delayed pressure urticaria: Clinicopathologic findings

Cited by 60 publications

References 10 publications

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Urticaria: current and future treatments

Current advances in the management of urticaria

Contact Info

Product

Resources

About